AtriCure price target raised to $48 from $36 at Stifel

Stifel raised the firm’s price target on AtriCure (ATRC) to $48 from $36 and keeps a Buy rating on the shares. For 2025, AtriCure reiterated their January 13 initial revenue guidance of $517M-$527M, which brackets the firm’s prior sales projection so Stifel’s outlook “remains little-changed,” the analyst tells investors.